Sign In
Buy IBRX
$7.79
-0.430 (-5.23%)
At Close: Jul 13, 2026
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
02:29pm, Monday, 13'th Jul 2026
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather tha
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
12:04pm, Friday, 10'th Jul 2026
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
ImmunityBio: A Long-Term Bull Case Worth Watching
04:07am, Tuesday, 07'th Jul 2026
ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
09:01am, Monday, 29'th Jun 2026
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
02:00pm, Monday, 01'st Jun 2026
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
01:51pm, Monday, 01'st Jun 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American So
IBRX and the BCG Shortage: Deals That Could Expand Demand
02:31pm, Friday, 29'th May 2026
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
ImmunityBio: Anktiva Explained and What Comes Next
02:25pm, Friday, 29'th May 2026
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
IBRX Stock Outlook After Q1 Results and a New FDA Review
02:25pm, Friday, 29'th May 2026
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
The $13 Million Company Teaching the Immune System to Hunt Cancer
09:00am, Friday, 29'th May 2026
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such in
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, bot
LOS ANGELES, May 26, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded c
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
09:05am, Tuesday, 26'th May 2026
LOS ANGELES, May 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors th
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX
09:00am, Tuesday, 26'th May 2026
NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class pe
